Jose Fernando Moura, PhD· @FernandoOnco · X·· 15 hours agoScore45
Body
@myESMO #Tarlatamab #sclc #ESMO26 @StephenVLiu @BalazsHalmosMD @OncoAlert
62 views · 2 likes · 0 reposts · 0 replies
Conference abstracts
3821Pmatched by SCLC
Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.org3848Pmatched by SCLC
Cytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis
https://esmocongress.esmo.orgLBA3matched by Presidential Symposium I
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgSource: Jose Fernando Moura, PhD · x.com